Sign in or create an account to add this stock to your watchlist.
About Leap Therapeutics (NASDAQ:LPTX)
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. The company's clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Its clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-2.58
Forward P/E Ratio-3.31
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.11 per share
Price / Book7.69
EPS (Most Recent Fiscal Year)($3.31)
Return on Equity-182.53%
Return on Assets-96.58%
Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions
What is Leap Therapeutics' stock symbol?
Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
How were Leap Therapeutics' earnings last quarter?
Leap Therapeutics (NASDAQ:LPTX) released its earnings results on Friday, May, 11th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.24. View Leap Therapeutics' Earnings History.
When is Leap Therapeutics' next earnings date?
What price target have analysts set for LPTX?
1 brokerages have issued 12-month target prices for Leap Therapeutics' shares. Their forecasts range from $12.50 to $12.50. On average, they expect Leap Therapeutics' stock price to reach $12.50 in the next year. View Analyst Ratings for Leap Therapeutics.
What are Wall Street analysts saying about Leap Therapeutics stock?
Here are some recent quotes from research analysts about Leap Therapeutics stock:
- 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (5/17/2018)
- 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)
Who are some of Leap Therapeutics' key competitors?
Some companies that are related to Leap Therapeutics include Mersana Therapeutics (MRSN), Isotechnika Pharma (AUPH), Clementia Pharmaceuticals (CMTA), Concert Pharmaceuticals (CNCE), Cytokinetics (CYTK), Obseva (OBSV), Evolus (EOLS), Zymeworks (ZYME), ProMetic Life Sciences (PFSCF), Dermira (DERM), Innate Pharma (IPHYF), Sinovac Biotech (SVA), Merus (MRUS), Clearside Biomedical (CLSD) and Depomed (DEPO).
Who are Leap Therapeutics' key executives?
Leap Therapeutics' management team includes the folowing people:
- Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 64)
- Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 49)
- Mr. Augustine J. Lawlor, Chief Operating Officer (Age 62)
- Dr. Cynthia A. Sirard M.D., Chief Medical Officer
Has Leap Therapeutics been receiving favorable news coverage?
News coverage about LPTX stock has trended somewhat positive this week, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Leap Therapeutics earned a daily sentiment score of 0.19 on Accern's scale. They also assigned news articles about the company an impact score of 45.52 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Leap Therapeutics' major shareholders?
Leap Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sphera Funds Management LTD. (2.95%), DAFNA Capital Management LLC (1.38%), JPMorgan Chase & Co. (0.28%), Point72 Asset Management L.P. (0.19%), Spark Investment Management LLC (0.12%) and Millennium Management LLC (0.09%). View Institutional Ownership Trends for Leap Therapeutics.
Which major investors are buying Leap Therapeutics stock?
LPTX stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., DAFNA Capital Management LLC, JPMorgan Chase & Co., Point72 Asset Management L.P., Spark Investment Management LLC and Millennium Management LLC. View Insider Buying and Selling for Leap Therapeutics.
How do I buy shares of Leap Therapeutics?
Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Leap Therapeutics' stock price today?
One share of LPTX stock can currently be purchased for approximately $8.54.
How big of a company is Leap Therapeutics?
Leap Therapeutics has a market capitalization of $125.14 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.
How can I contact Leap Therapeutics?
Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.
MarketBeat Community Rating for Leap Therapeutics (LPTX)MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Leap Therapeutics (NASDAQ:LPTX) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Leap Therapeutics (NASDAQ LPTX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 58.70%
Institutional Ownership Percentage: 17.03%
Leap Therapeutics (NASDAQ LPTX) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/14/2017||Augustine Lawlor||COO||Buy||1,057,769||$6.09||$6,441,813.21|| |
Leap Therapeutics (NASDAQ LPTX) News Headlines
Leap Therapeutics (NASDAQ:LPTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Leap Therapeutics (NASDAQ:LPTX) Income Statement, Balance Sheet and Cash Flow Statement
Leap Therapeutics (NASDAQ LPTX) Stock Chart for Friday, May, 25, 2018